KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Selling, General & Admin · Q4 FY2026 · quarter ended Dec 2025
Selling, general & admin of $48.44M in Q4 FY2026
Q4 FY2026 selling, general & admin was $48.44M. Trailing-twelve-month selling, general & admin was $198.25M.
Context
- Selling, general & admin amounted to 249.6% of revenue in FY2026.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $258.59M (+40.7%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- $48.44M+4.1% QoQ
- Last fiscal yearDec 2025
- $183.74M— YoY
- LTMDec 2025
- $198.25M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +40.7% | — |
| 3-year CAGR | — | +44.4% | — |
| 5-year CAGR | +33.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2026
- 183.74M USD
- Year-over-year change
- +58.0%
- 4-year CAGR
- +62.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | 183.74M | +58.0% |
| FY2025 | 2025-04-30 | 116.29M | +114.2% |
| FY2024 | 2024-04-30 | 54.28M | +77.4% |
| FY2023 | 2023-04-30 | 30.6M | +15.7% |
| FY2022 | 2022-04-30 | 26.45M | — |
Selling, General & Admin vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 selling, general & admin of $198.25M is the highest of the 10 companies compared; the peer median is $54.46M.
- Selling, general & admin amounts to 171.0% of revenue for KALV, versus a peer median of 98.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $198.25M | — | — | 171.0% | |
| LTM Mar 2026 | $118.84M | +5.8% | +1.0% | 39.6% | |
| LTM Mar 2026 | $88.42M | +83.1% | +48.1% | 178.3% | |
| LTM Mar 2026 | $82.03M | +32.5% | — | 103.6% | |
| LTM Mar 2026 | $76.67M | +0.6% | +17.4% | 120.8% | |
| LTM Mar 2026 | $54.46M | -19.1% | +6.0% | 94.0% | |
| LTM Mar 2026 | $47.81M | -5.9% | +14.2% | 54.2% | |
| LTM Mar 2026 | $47.72M | +35.5% | -7.5% | 85.9% | |
| LTM Mar 2026 | $33.4M | -31.3% | -6.4% | 337.6% | |
| LTM Mar 2026 | $25.39M | +44.8% | -5.3% | — | |
| Peer median (excluding KALV) | $54.46M | +5.8% | +3.5% | 98.8% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 73.62M |
| Cost of Revenue | 0 | 0 | 86.17M | 0 | 6.08M |
| Gross Profit | 0 | 0 | (86.17M) | 0 | 67.54M |
| Gross Margin | — | — | — | — | 91.7% |
| Research & Development | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
| Selling, General & Admin | 26.45M | 30.6M | 54.28M | 116.29M | 183.74M |
| Operating Expenses | 96.61M | 110.87M | 54.28M | 188M | 239.38M |
| Depreciation & Amortization | 564K | 718K | 816K | 941K | 1.45M |
| EBITDA | (80.75M) | (94.37M) | (134.28M) | (173.33M) | (150.62M) |
| EBITDA Margin | — | — | — | — | -204.6% |
| Operating Income | (96.61M) | (110.87M) | (140.45M) | (188M) | (171.84M) |
| Operating Margin | — | — | — | — | -233.4% |
| Interest Income | 1.09M | 2.23M | 3.9M | 6.44M | 8.68M |
| Interest Expense | 0 | 0 | 0 | 5.79M | 19.34M |
| Other Income / Expenses | 14.27M | 17.96M | 5.35M | 7.94M | 420K |
| Income Before Tax | (82.34M) | (92.91M) | (135.1M) | (180.05M) | (171.42M) |
| Pre-Tax Margin | — | — | — | — | -232.9% |
| Income Tax Expense | 0 | 0 | (8.45M) | 3.39M | (7.13M) |
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Net Margin | — | — | — | — | -223.2% |
| EPS (Basic) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| EPS (Diluted) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| Weighted Avg Shares | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
| Weighted Avg Shares (Diluted) | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.